NanoViricides Reports FluCide™ Samples Were Shipped To BASi For Start of Safety/Toxicology Studies; Also Reports That Ebola Drug Candidates are Being Synthesized

WEST HAVEN, Conn.-- NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”) reports that it has shipped FluCide™ to BASi for the start of toxicology studies. NanoViricides has chosen BioAnalytical Systems Inc. Toxicology Services (“BASi”) of West Lafayette, Indiana to perform our safety/toxicology studies as needed for an IND submission of the Injectable FluCide drug candidate.

In other news, NanoViricides reported that the synthesis of its anti-Ebola second generation drug candidates has started. We anticipate being able to evaluate these against Ebola virus with certain of our previous collaborators.

Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients

-- Primary endpoint was met for 50 mg twice daily dosing

FREMONT, Calif., Oct. 1, 2014  -- Ardelyx, Inc. (ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C).  Results from this study demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo. At the 50 mg dose, the study met its primary efficacy endpoint of an increase in the complete spontaneous bowel movement (CSBM) responder rate. Most secondary endpoints, including abdominal pain and other abdominal and IBS-C symptoms, demonstrated clinically meaningful improvements. Tenapanor was well-tolerated, and the safety results were consistent with those observed in previous tenapanor trials.

By Jon C Ogg - 24wallst.com

Tuesday brought the very unfortunate news that a confirmed case of Ebola has arrived in the United States. With the CDC not releasing enough data on the patient, there could be an opportunity for traders on both sides of the Ebola story. 24/7 Wall St. has included a few of the companies that are seeing gains from the Ebola theme.

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares were up only 5.3% shortly ahead of the opening bell on 20,000 shares or so. The stock was initially up 5% at $9.78 and then was up over 10% and just above $10 in the after-hours on Tuesday, but that was after a 6.7% drop to $9.78 in regular trading. Its 52-week range is $4.55 to $14.62. J.P. Morgan gave this an Overweight rating and $20 price target on August 8.

[ Read the Whole Article With All Related Stocks ]